Effects of Intravenous GC4419 on the Incidence and Severity of Esophagitis Due to Chemoradiotherapy for Lung Cancer
Clinical trial NCT04225026 · TERMINATED
Trial details
- NCT number
- NCT04225026
- Sponsor
- Galera Therapeutics, Inc.
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-12-19
- Primary completion
- 2021-12-28
- Enrollment
- 39
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.